

(12) SOLICITUD INTERNACIONAL PUBLICADA EN VIRTUD DEL TRATADO DE COOPERACIÓN EN MATERIA DE PATENTES (PCT)

(19) Organización Mundial de  
Propiedad Intelectual  
Oficina internacional



(10) Número de Publicación Internacional  
**WO 2012/041261 A3**

(43) Fecha de publicación internacional  
5 de abril de 2012 (05.04.2012)

WIPO | PCT

- (51) **Clasificación Internacional de Patentes:**  
A61K 38/08 (2006.01) C07K 7/06 (2006.01) [CU/CU]; Calle 375 No. 17836 Apto 18 entre 178 y 184. Mulgoba, Boyeros, 19290 La Habana (CU).
- (21) **Número de la solicitud internacional:** PCT/CU2011/000006 (74) **Mandatario:** RUIZ SOTOLONGO, Maria, Lourdes; Claim S. A., Lamparilla No. 2, Edificio Lonja del Comercio, Planta Baja, Sección G, La Habana 10200 (CU).
- (22) **Fecha de presentación internacional:** 27 de septiembre de 2011 (27.09.2011) (81) **Estados designados (a menos que se indique otra cosa, para toda clase de protección nacional admisible):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (25) **Idioma de presentación:** español
- (26) **Idioma de publicación:** español
- (30) **Datos relativos a la prioridad:** 2010-0186 27 de septiembre de 2010 (27.09.2010) CU (84) **Estados designados (a menos que se indique otra cosa, para toda clase de protección regional admisible):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), euroasiática (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), europea (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) **Solicitante (para todos los Estados designados salvo US):** GRUPO EMPRESARIAL DE PRODUCCIONES BIOFARMACEUTICAS Y QUIMICAS [CU/CU]; Avenida Independencia Km 16 1/2, Santiago de las Vegas, Boyeros, La Habana 17200 (CU).
- (72) **Inventores; e**
- (75) **Inventores/Solicitantes (para US solamente):** FRAGA CASTRO, José, Antonio [CU/CU]; Calle 5ta. No. 8607 Apto 2, entre 86 y 88. Playa, La Habana 11300 (CU). MEDINA GALL, Regla, María [CU/CU]; Calle 308 Edif.13, Apto 1, entre 21 E y 21 B. Reparto Barbosa, Playa, La Habana 11300 (CU). DIAZ GARCIA, Alexis [CU/CU]; Zapata No. 1465, Apto 14 entre A y B, Vedado, Plaza, La Habana 10400 (CU). GUEVARA ORELLANA, Irania [CU/CU]; Calle 373, Edificio Mulgoba. Boyeros, La Habana 19290 (CU). RODRIGUEZ TORRES, Caridad, Clara [CU/CU]; Calle 16 No. 230 entre B y C. Lawton, 10 de Octubre, La Habana 10500 (CU). RODRIGUEZ COIPEL, Judith [CU/CU]; Calle 3ª edif. B apto 2, Rpto. Santa Mónica. Quivicán, Mayabeque 33500 (CU). RIQUENES GARLOBO, Yanelis [CU/CU]; Línea No. 1253 Apto. 11 esq. 20, Vedado, Plaza, La Habana 10400 (CU). GONZALEZ MARRERO, Isbel [CU/CU]; Estrada Palma no. 509 Apto 4, entre Juan Delgado y Goicuría. Santos Suárez. 10 de Octubre, La Habana 10500 (CU). PEREZ CAPOTE, María, Regla
- Publicada:**
- con informe de búsqueda internacional (Art. 21(3))
  - antes de la expiración del plazo para modificar las reivindicaciones y para ser republicada si se reciben modificaciones (Regla 48.2(h))
  - con la parte de lista de secuencias de la descripción (Regla 5.2(a))
- (88) **Fecha de publicación del informe de búsqueda internacional:** 22 de noviembre de 2012



WO 2012/041261 A3

(54) **Title:** PEPTIDES FROM THE VENOM OF THE RHOPALURUS JUNCEUS SCORPION AND PHARMACEUTICAL COMPOSITION

(54) **Título:** PEPTIDOS DEL VENENO DE ESCORPION RHOPALORUS JUNCEUS Y COMPOSICION FARMACEUTICA

(57) **Abstract:** The invention relates to novel peptides obtained from the venom of the Rhopalurus junceus scorpion, characterised by a high content of proteins, lipids, carbohydrates, amino acids, inorganic salts and other ions including peptides as active principles. The invention also relates to a formulation used as a drug due to the properties thereof, such as its anti-carcinogenic, analgesic and anti-inflammatory properties which improve the quality of life of cancer patients.

(57) **Resumen:** La presente invención se relaciona con nuevos péptidos obtenidos a partir del veneno de escorpión Rhopalurus junceus el que se caracteriza por un alto contenido en proteínas, lípidos, carbohidratos, aminoácidos, sales inorgánicas y otros iones incluidos péptidos como principios activos. La invención también incluye una formulación empleada como medicamento por sus propiedades como anticancerígeno, analgésico y antiinflamatorio que conducen a la elevación de los índices de la mejoría de la calidad de vida en pacientes con enfermedades oncológicas.

## Peptides from the venom of the *Rhopalurus junceus* scorpion and pharmaceutical composition.

### Field of the Invention

5

The present invention is linked essentially to the pharmaceutical industry and particularly to the identification of peptides obtained from the *Rhopalurus junceus* scorpion, Buthidae family, *Rhopalurus* genus, *R. junceus* species, common name “red” scorpion, venom which contains a mix of peptides, proteins, amino acids and free amines.

10

### Previous art.

Scorpions are land arthropods and, as poisonous animals, they are the oldest group as they were the first ones to develop on Earth. There are approximately over 1 500 scorpion species whose taxonomic classification is *Phylum Arthropoda*, *Arachnida* Class scorpions. In their natural habitat, the venom of scorpions is an opalescent, milky fluid with pH 7.12 and it contains mucus, lipids, carbohydrates, amino acids, inorganic salts, low-molecular weight organic molecules and a wide variety of proteins with molecular weights ranging 3 kDa-90 kDa which are the main component. Recently, research on scorpion venoms has taken momentum due to their high content of peptides that have shown a wide spectrum of pharmacological activity, for which reason they are invaluable tools for biomedical research (Martin-Eauclaire M-F, Segoard M, Ramos C, Cestele S, Bougis PE, and Svenson B, Production of active insect-specific scorpion neurotoxin in yeast. *Eur.J. Biochem.* 1994; 223; 637-45; Bednarek MA, Bugianesi RM, Leonard RJ, Felix JP. Chemical synthesis and structure-function studies of margatoxin, a potent inhibitor of voltage dependent potassium channel in human T lymphocytes. *Biochem Biophys Res Commun.* 1994 Jan 28; 198(2):619-25.) In this sense, recent years have seen a greater number of patent and non-patent publications about the activity of these toxins and their derivatives like anti-inflammatory

20

25

30

components (Rajendra W, Armugan A and Jeyaseeian K. Toxins in anti-nociception and anti-inflammation. *Toxicon* 2004 July; 44(1):1-17); analgesics (Guan RJ, Wang CG, Wang M and Wang DC. A depressant insect toxin with a novel analgesic effect from scorpion *Buthus martensii* Karsch. *Biochem. Biophys. File* 2001; 1549(1):9-18), in cancer treatment (Liu YF, Ma RL, Wang SL, Duan ZY, Zhang JH, Wu LJ and Wu CF. Expression of an antitumor-analgesic peptide from the venom of Chinese scorpion *Buthus martensi* Karsch in *Escherichia coli*. *Protein Expr. Purif.* 2003; 27(2):253-8; Wang WX, Ji YH. Scorpion venom induces glioma cell apoptosis in vivo and inhibits glioma tumor growth in vitro. J Neurooncol. 2005 May; 73(1):1-7) and neurodegenerative diseases (Rajendra W, Armugan A and Jeyaseelan K. Toxins in anti-nociception and anti-inflammation. *Toxicon* 2004 July; 44(1):1-17.) Inventions whose composition include scorpion and/or its venom comprise a wide range of formulations intended for cancer therapy. The authors of the 1993 CN 1073480 and CN 1076858 patent papers refer they have obtained a wine allowing for cancer treatment and prevention, in both cases by mixing scorpion and other plant and animal materials.

Scorpions are one of the components of formulations in the form of tablets for treating primary liver cancer (CN 1265901, 2000 and CN 1279088, 2001) and of capsules which inhibit tumor cell growth and can cure cancer in patients (CN 1391941, 2003.) Other patents describe various formulations for cancer treatment (CN 1252321; 2000 CN 1316249, 2001; CN 1399979, 2003.)

There are also patents on the exclusive use of toxins obtained from scorpion venom which act on specific tumor cell types. Early works on scorpion venom toxins referred that a peptide was obtained from the *Leiurus quinquestriatus* Hebrew scorpion. That toxin, which is a 4 KDa peptide named chlorotoxin, has a capacity to bind with the chloride channels expressed in gliomas (primary brain tumors from the glia (De Bin JA, Maggio JE, Strichartz GR. Purification and characterization of chlorotoxin, a chloride channel ligand from venom of the scorpion. *Am J Physiol* 1993; 264:361-369.) Based on this breakthroughs, in 1999 Ullrich et al. described in US patent 5 905 027 a diagnostic method for treating

gliomas. Other works taking the specific action of chlorotoxin on certain cell receptors in gliomas as a basis showed that this toxin is a highly specific marker for other kinds of tumors whose cells have a common embryonic origin with the Central Nervous System (CNS) cells (Lyons SA, O'Neal J, Sontheimer H: Chlorotoxin, a scorpion derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. GLIA 2002; 39:162-73.) Additionally, recent works have shown that chlorotoxin not only inhibits "in vitro" glioma growth but has a capacity to prevent the invasion and spreading of this kind of tumors into brain regions which have not been damaged due to its specific and selective interaction with methalloproteinases, which are enzymes having to do with the high invasive rate of this kind of cancer (Deshane J, Garner CC and Sontheimer H: Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem 2003; 278:4135-44.) In 2004, another patent on the antitumor activity of an isolated toxin from the *Buthus martensis karsh* scorpion on animal-implanted tumors (EP20020774251) was published.

In some cases, there is a wide variety of formulations with the ability to treat or cure cancer under the described patents. Yet, these cases do not prove this quality is unique of some of the types of scorpions and toxins involved in their manufacturing. On the other hand, the described toxins obtained from *Leiurus quinquestriatus* scorpions do not show antitumor activity per se, as in the case of chlorotoxin and *Buthus martensis karsh*, which can be used only to treat certain types of tumors as isolated toxins and not as a mix of toxins in whole venom.

In Cuba, there is a *Rhopalurus junceus* scorpion venom diluted solution whose antitumor activity has been proved empirically in studies. During this work, the solution was administered to domestic animals with spontaneous tumors and tumor reduction and obliteration and good survival were observed (CU 22413 A1.) This invention has distinctive features in the sense there is no knowledge about any pharmaceutical formulation for the therapy and life quality improvement which are claimed by this invention.

### Details description of the invention

The composition and pharmacological properties of *Rhopalurus junceus* scorpion venom and/or its derivatives make it a highly valuable natural drug and its anti-inflammatory, analgesic and anti-carcinogenic effects differentiate it substantially from other similar products in the market. It is a totally natural drug combining high-efficacy components to fight tumor cells (peptides) and others that provide it with analgesic and anti-inflammatory activity. Additionally, it has beneficial effects through the induction of tumor cell apoptosis and through its analgesic and anti-inflammatory properties. These features make it very valuable for improving the quality of life of patients suffering from cancer diseases and their related inflammatory conditions. It has been found that the composition of the natural product resulting from this invention includes a series of low molecular weight proteins with *in vitro* anti-carcinogenic activity whose action confirms potential *in vivo* antitumor activity.

One of the purposes of this invention is determining the composition of and describing the peptides which are the active principles with antitumor activity found in venom. The summaries on qualitative composition, chemical screening, chemical-physical properties and pharmacological activity of scorpion venom are shown in Tables I, II, III, IV, V, VI and VII, respectively.

Table I. Chemical screening of *Rhopalurus junceus* whole venom used in formulations of this invention.

Assay	Results
Dragendorff Assay	Negative
Iron Chloride Assay	Negative
Shinoda Assay	Negative
Lieberman-Burchard Assay	Negative

Ninhydrin Assay	Positive
Carbohydrates	Positive
Lipids	Positive

Table II. Determination of metal ions in *Rhopalurus junceus* whole venom.

Sample	Na (mg/L)	Mg (mg/L)	K (mg/L)	Cu (mg/L)	Zn (mg/L)	Cd (mg/L)	Pb (mg/L)
Scorpion venom	114±21	4.12±0.28	4.66±0.35	0.069±0.006	11.18±0.7	<0.004*	<0.01*

5

\*Heavy metals with levels below the lower limit

Table III. Chemical-physical properties of *Rhopalurus junceus* scorpion venom used in formulations for this invention.

10

Property	Acceptance index
pH	5-7
Protein content	5-15 mg/mL
Appearance	Opalescent
Color	Whitish

Table IV. Table of relative molecular weights (RMW) of proteins in scorpion venom obtained through molecular exclusion using low-pressure liquid chromatography and polyacrylamide gel electrophoresis (SDS-PAGE.)

15

Relative molecular weights
$\geq 72$ kDa
60 kDa
45 kDa
30 kDa
14 kDa
8 kDa
$\leq 4$ kDa

Table V. Active principles with toxic activity on tumor cells identified from *Rhopalurus junceus* whole venom.

5

Peptide	Molecular weight	Amount of amino acids
RjLB-01	544.42 Da	10
RjLB-03	1964.0 Da	17
RjLB-04	4748.14 Da	43
RjLB-05	908.0 Da	8
RjLB-07	707.03 Da	7
RjLB-08	712.42 Da	17
RjLB-09	1203.44 Da	12
RjLB-14	5930.45 Da	50

Table VI. Summary of toxicological studies

General toxicology		<i>R. juncus</i> venom (mg/kg)	Effect
Acute toxicology			
Oral route		2000	N.E.
IP route		5-20	DL <sub>50</sub> =16,41mg/kg (M y H)
Irritability			
Dermal		-	N.E.
Ophthalmic		-	N.E.
Mouth mucose		-	N.E.
Repeat dose toxicity			
Repeat oral dose toxicity (28 days)		100	N.E.
Subchronic oral toxicity (90 days)		0,1-100	N.E.
Water and food intake			N.E.
Weight gain			N.E.
Hematological and biochemical parameters			N.E.
Relative weight of organs			N.E.
Pathological anatomy			N.E.
Especial toxicity		<i>R. juncus</i> venom (mg/kg)	Effect
Mice bone marrow micronuclei	Oral (acute)	2000	N.E.
	Oral (repeat doses, 28 days)	100	N.E.
	ip	4,10-13,13	N.E.

Legend: N.E.: No effect

Table VII. Summary of pharmacological studies

Pharmacology	Effect
Antiproliferative	Cytotoxicity in epithelial tumor cells
Antitumoral	Murine solid tumor growth retardation
Antimetastasic	Murine lung metastasis reduction
Analgesic	Reduced CNS and peripheral pain
Anti-inflammatory	Reduced inflammation after topical, oral and intraperitoneal administration

5

The following procedures were carried out in order to determine the composition of the mix in this invention.

- Determination of whole proteins through the Lowry method, modified.
- 10 • Chemical screening
- Separation of peptides as per molecular weight groups through low-pressure liquid chromatography separation using a 12 HR 10&30 Superose column.
- Polyacrylamide gel protein electrophoresis (SDS-PAGE.)
- 15 • Separation of whole venom and of peptides through high-resolution liquid chromatography using a reverse-phase C18 column.
- Determination of 220nm- and 280nm-wavelength UV spectra.
- Cell viability in normal and tumor cells.
- Analysis of each peptide of interest through mass spectrometry.

20

According to the results from acute and subchronic toxicity assays done in mice, the product from this invention is non-toxic.

The studies which are described in detail below as examples of the invention product do not limit the scope of this application whatsoever.

5 In order to carry out the experiments given as examples of work, several scorpions were chosen and their venom was extracted through electrical stimulation and diluted in adequately distilled water. It was later clarified by centrifugation at 10 000 rpm for 15 minutes to eliminate components such as mucus and cell debris. Venom protein content determination was performed through the Lowry method, which showed a 5-15 mg/mL concentration.

10

#### **Intraperitoneal (IP) administration route**

Assay substance and positive control were administered first. After 30 minutes, a 10-15 $\mu$ L croton oil solution was administered to each surface inside and outside 15 the right ear of animals and the left ear was used as control. After three hours, animals were sacrificed following the usual standards for the species (according to FELASA), both ears were severed and round 8-mm diameter samples were taken with a punch and weighed on an analytical scale.

#### **20 Topical administration route**

First, the 25-30 $\mu$ L croton oil solution was applied on each of the inner and outer surfaces of the animal's right ear and the left ear was used as control. Then the assay substance was given immediately. After three hours, animals were 25 sacrificed following the usual standards for the species (according to FELASA), both ears were severed and round 8-mm diameter samples were taken with a punch and weighed on an analytical scale.

#### **Oral administration route**

30

The 25-30µL croton oil solution was administered on each of the inner and outer surfaces of the animal's right ear and the left ear was used as control. Then the assay substance was administered by oral route immediately. After three hours, animals were sacrificed following the usual standards for the species (according to FELASA), both ears were severed and round 8-mm diameter samples were taken with a punch and weighed on an analytical scale.

Topical administration of croton oil provides a proper skin inflammation model for evaluating anti-inflammatory agents. The croton oil active principle is Phorbol-12-Myristate 13-Acetate (PMA), which is a potent pro-inflammatory agent whose epicutaneous application results in histological and biochemical changes including higher vascular permeability and vascular rupturing, leukocytary infiltration, protein C activation and a greater release of arachidonic acid and its metabolites. PMA is also known to be a powerful neutrophil activator and there is wide and powerful blood irrigation in the ear.

#### **IP administration route**

IP administration of the 1-5 mg/kg doses per body weight inhibited swelling induced by croton oil in mice ears (Table VIII), and the 3 mg/kg dose was more effective than the IP administration of 15 mg/kg dexamethasone in experimental animals as it had a higher inflammation inhibiting effect (97% vs 60.86%.) The 5 mg/kg dose did not differ statistically ( $p > 0.05$ ) from the positive control (dexamethasone.)

25

Table VIII. Effect of intraperitoneal administration of *R. junceus* venom in the mice ear edema model

Group		Extinction of edema (mg)	Inflammation inhibition, %
Control		7,043 ± 0,27	-
<i>R. Junceus</i> venom	1 mg/kg	5,050 ± 1,47 b	27,12
	3 mg/kg	1,483 ± 0,93 c	97,46
	5 mg/kg	4,020 ± 1,41 db	44,09
15 mg/kg dexamethasone		3,117 ± 1,09 d	60,86

Values are the mean ±SD. Groups having at least one common letter do not differ statistically. (p > 0.05.)

5

#### Oral administration route

Administration of 5-, 10- and 20-mg *R. junceus* venom results in significant ear weight loss compared to the negative control group (Table IX), but it doesn't compare statistically to swelling inhibition induced by dexamethasone, which is a good steroidal anti-inflammatory drug that inhibits phospholipase A<sub>2</sub> (the enzyme that is the route for arachidonic acid.)

Table IX. Effect of oral administration of *R. junceus* venom in the ear edema model in mice.

Group		Extinction of edema (m/g)	Inflammation inhibition, %
Control		11,28 ± 1,29 a	-
<i>R. junceus</i> venom	5 mg/kg	7,68 ± 0,50 c	35,72
	10 mg/kg	8,05 ± 0,57 c	37,39
	20 mg/kg	7,76 ± 1,01 c	38,02
15 mg/kg dexamethasone		4,87 ± 0,95 b	53,70

Values are the mean  $\pm$ SD. Groups having at least one common letter do not differ statistically. ( $p > 0.05$ .)

### Topical administration route

5

Topical administration of *R. junceus* venom resulted in auricular edema reduction compared to the control group, as shown in Table X.

Table X. Effect of topical administration of *R. junceus* venom in the ear edema model in mice.

10

Group		Extinction of edema (mg)	Inflammation inhibition, %
Control		12,00 $\pm$ 0,48 a	-
<i>R. junceus</i> venom	10 mg/kg	8,87 $\pm$ 0,66 c	28,23
	20 mg/kg	8,25 $\pm$ 0,83 c	21,70
Bencydamine		4,87 $\pm$ 1,40 b	67,60

Values are the mean  $\pm$ SD. Groups having at least one common letter do not differ statistically. ( $p > 0.05$ .)

15

Table XI shows the results from the study that was done. Oral administration of *R. junceus* venom brought a slight granulomatose tissue inhibition that took place compared to the negative control group, which suggests activity in the proliferative phase of inflammation. The two studied product doses had a similar effect.

20

Table XI. Effect of *R. junceus* venom on cotton pellet-induced granulomas in rats.

Group	Granuloma weight (mg)	Inhibition, %
Control	103,33 ± 5,08 a	-
3 mg/kg dexamethasone	55,40 ± 14,84 b	44,09
10 mg/kg <i>R. Junceus</i> venom	80,60 ± 4,74 c	20,95
20 mg/kg <i>R. Junceus</i> venom	83,10 ± 6,52 c	18,49

Values are the mean ±SD. Groups having at least one common letter do not differ statistically. (p > 0.05.)

5

Table XII shows granuloma weight and carmine content values for the different experimental groups. The toxin lowered the granuloma weight 1.32 and 2.05 times compared to the control group (p < 0.05) with its 3- and 5-mg/kg doses, respectively.

10

Angiogenesis is a key process for tumor growth and metastasis, so having products which can inhibit this complex process is an alternative for treating tumor diseases.

15 Carmine content is an indicator of the formation of new blood vessels in the air-pouch granuloma. Toxin administration reduced new blood vessel formation in the granulomatose tissue by 39.22% and 69.24% with the 3- 5-mg/kg (IP) doses, respectively, with a significant statistical difference between all experimental groups

20 (p < 0.001.)

Table XII. Effect of *R. Junceus* venom administered intraperitoneally on granuloma weight and carmine content in adjuvant-induced inflammatory angiogenesis in rats (n=10.)

Group		Granuloma weight (g±SD)	Carminic content (A±SD)
Control		5,26 ± 1,11 <sup>a</sup>	0,413 ± 0,014 <sup>a</sup>
<i>R. junceus</i> venom	3 mg/kg	3,59 ± 0,33 <sup>b</sup>	0,251 ± 0,015 <sup>b</sup>
	5 mg/kg	2,56 ± 0,74 <sup>b</sup>	0,127 ± 0,020 <sup>c</sup>

Groups having at least one common letter do not differ statistically ( $p > 0.05$ .)

A: Absorbance at 490 nm

5

Table XIII shows the results of the analgesic effect of *R. junceus* venom inoculated intraperitoneally to the 3% acetic acid-induced contorsions model in mice.

All groups treated with the different venom doses showed much lower ( $p < 0.05$ ) abdominal constrictions compared to the negative control group. The 2.5- and 7.5-mg/kg venom doses had a similar effect than that in the group given aspirin, a known analgesic drug. On the other hand, the 5.0 mg/kg *R. Junceus* venom dose showed a higher inhibition (87.74%) than that obtained from the administration of 100 mg/kg aspirin (49.28%).

15

Table XIII. Effect of the intraperitoneal administration of *R. junceus* venom in the acetic acid-induced abdominal contorsions model.

Experimental groups	Doses (mg/kg)	No. contorsions X ± DS	% inhibition of No. of contorsions
CN	-	36,22 ± 5,11 <sup>a</sup>	-----
ASA	150	18,37 ± 4,63 <sup>b</sup>	49,28
Venom of <i>R. junceus</i>	1	22,25 ± 4,53 <sup>b</sup>	38,57
	2,5	17,87 ± 5,59 <sup>b</sup>	50,66
	5	4,44 ± 4,33 <sup>c</sup>	87,74
	7,5	17,86 ± 5,30 <sup>b</sup>	50,69

NC: Negative control; No: Number

Experimental groups	Dose (mg/kg)	No. of contorsions $X \pm DS$	Inhibition in the No. of contorsions, %
NC	-	$36,22 \pm 5,11^a$	-----
ASA	150	$18,37 \pm 4,63^b$	49,28
<i>R. juncus</i> venom	1	$22,25 \pm 4,53^b$	38,57
	2,5	$17,87 \pm 5,59^b$	50,66
	5	$4,44 \pm 4,33^c$	87,74
	7,5	$17,86 \pm 5,30^b$	50,69

ASA: Aspirin

Groups having at least one common letter do not differ statistically ( $p > 0.05$ .)

## 5 Oral route administration

As evidenced in Table XIV, all groups which were given various venom doses showed a markedly lower number ( $p < 0.05$ ) of abdominal constrictions compared to the negative control group. A comparison of the venom doses used with the positive control group (aspirin) showed a marked analgesic effect. Doses of 10-, 15- and 20-mg/kg *R. juncus* venom inhibited abdominal contractions in a way similar to that of aspirin. Whereas the 50-mg/kg dose did not bring about statistically significant differences from the positive control, it attained a 54.78% inhibition of abdominal contorsions in the experimental animals.

15

Table XIV. Inhibition of acetic acid-induced abdominal contorsions after the oral administration of *R. juncus* venom.

Experimental groups	Dose (mg/kg)	Inhibition in the No. of contorsions, %
NC	-	-----
ASA	150	47.01
<i>R. junceus</i> venom	1	18,84
	5	32,84
	10	36,23
	15	39,85
	20	43,19
	50	54,78

NC: Negative control

ASA: Aspirin

5 • Thermal analgesia model in mice.

The method described in Drug Discover was used.

10 OF1 male mice weighing an average 20-25g from the National Center for Laboratory Animal Production (CENPALAB) were used.

(pag. 16)

15 The animals were placed on a (UGO-Basile) hot plate at a 55°C constant temperature both before and after administering the assay substance. The latency of the nociceptive response in the form of hind leg licking or jumping was measured. Only those animals which showed a nociceptive response within 20 seconds were chosen for the assay. Selection ended at 40 seconds.

After administering a physiological saline solution to the negative control, 4% codeine to the positive control, and the various *R. junceus* venom doses, response latency time in each animal were measured after 2-3 hours.

5 During this work, nociceptive reactivity to a thermal stimulus in mice was measured using the hot plate assay, which is an acute pain sensitivity test to detect opiod analgesia as well as some kinds of significant hyperanalgesic dorsal spine reactions. A substance is considered to have significant analgesic properties when an animal's normal reaction time doubles with its administration.

10

The analgesic effect of *R. junceus* venom is shown in Figure 1 and Table XV. Results indicate that IP administration of three doses of the product significantly reduced hot plate thermal stimulation. Figure 1 shows that the three *R. junceus* venom doses significantly expand nociceptive response latency spans during the hot plate assay with mice.

15

Pain inhibition in the various experimental groups is shown in Table XV. A powerful heat-induced inhibition of algesia is observed, with the highest inhibition taking place 2 hours after administration. There is a potent effect after three hours, and although 2.5- and 7.5-mg/kg doses have a similar effect on the positive control it is the higher dose which has a longer effect which is greater than that of codeine.

20

Table XV. Effect of *R. junceus* venom administration in the hot plate model.

Group	Dose (mg/kg)	Inhibition, %	
		2 h	3 h
Control	-	26,52 <i>a</i>	16,76 <i>a</i>
<i>R. junceus</i> venom	2,5	173,96 <i>b</i>	92,53 <i>b</i>
	5,0	109,19 <i>c</i>	36,31 <i>a</i>
	7,5	145,55 <i>bc</i>	165,54 <i>c</i>
Codeine	40	120,35 <i>c</i>	94,17 <i>b</i>

Groups having at least one common letter do not differ statistically ( $p > 0.05$ .)

- 5 The results of the hot plate test evidence that the *R. Junceus* venom has an anti-cociceptive effect on the central nervous system that is higher than the one on the bone marrow as a greater and more complex neuron integration is needed for the licking and jumping response.
- 10 Table XVI. Pro-oxidative potential of *R. junceus* scorpion venom in the model for *Fenanthrolin/Cu<sup>2+</sup>*-induced DNA damage.

Assay substance	Concentration (**/mL)	Extent of damage to DNA (****at 532 nm; Median $\pm$ SD)
Negative control	-	0,069 $\pm$ 0,004
<i>R. junceus</i> scorpion venom	7,50	0,023 $\pm$ 0,009*
	18,70	0,36 $\pm$ 0,002*
	37,50	0,047 $\pm$ 0,003*
	56,20	0,069 $\pm$ 0,012
	75,0	0,075 $\pm$ 0,011
Ascorbic acid	200 $\mu$ M	0,130 $\pm$ 0.006*

Different letters mean a statistical difference ( $p < 0.05$ ) compared to control.

15

Table XVII. Pro-oxidative potential of *R. junceus* scorpion venom in the model for *Fenanthrolin/Cu<sup>2+</sup>*-induced DNA damage.

Assay substance	Concentration ( $\mu\text{g/mL}$ )	Extent of damage to DNA (OD at 532 nm: Median $\pm$ SD)
Negative control	-	0.40 $\pm$ 0,005
<i>R. junceus</i> scorpion venom	4,50	0,024 $\pm$ 0,006
	9,01	0,026 $\pm$ 0,010
	18,02	0,037 $\pm$ 0,008
	36,04	0,024 $\pm$ 0,001
	90,11	0,039 $\pm$ 0,001
Ascorbic acid	200 $\mu\text{M}$	0,647 $\pm$ 0,016*

Different letters mean a statistical difference ( $p < 0.05$ ) compared to control.

- 5 Table XVIII. Cells used in studies to evaluate the *in vitro* biological activity of *R. junceus* scorpion venom.

Cell lines	Growth form	CC <sub>50</sub> (mg/mL)
HeLa (human cervix carcinoma)	single-layer	1
HEp-2 (human larynx epidermoid carcinoma)	single-layer	0,78
NCI-H292 (human lung mucoepidermoid carcinoma)	single-layer	0,69
A549 (human lung carcinoma)	single-layer	0,62
U937 (human histiocytic lymphoma)	suspension	ND
L929 (murine fibrosarcoma)	single-layer	1,3
S-180 (murine sarcoma)	suspension	ND
F311 (murine mammary adenocarcinoma)	single-layer	1,2
MRC-5 (human lung fibroblasts)	Single-layer	2,2
Vero (African green monkey normal kidney cells)	Single-layer	ND

MDCK (normal dog kidney cells)	single-layer	ND
N <sub>2</sub> A (murine neuroblastoma cells)	single-layer	1,4
Macrophages (extracted from Balb/c mice peritonea)	-	ND
Lymphocytes (extracted from Balb/c mice spleens)	suspension	ND

ND non-determined CC<sub>50</sub>: median cytotoxic concentration

Single-layer (carcinoma) growing cell cultures showed significant cell growth inhibition ( $p < 0.05$ ) and higher sensitivity than normal cells and tumor cells growing in a suspension.

A comparison between the CC<sub>50</sub> of a normal MRC-5 human cell line with human tumor cells showed that *R. juncus* scorpion venom has a differential and significant cytotoxicity ( $p < 0,05$ ) in tumor cells compared to normal cells (Table XVIII.)

Venom exposure provoked significant growth inhibition ( $p < 0.05$ ) in human and murine tumor cell lines in single-layer growing conditions. The U937 and S-180 tumor cell lines (both of which grew in suspension) showed less sensitivity to the administration of the venom; the only effect was a slightly lesser growth (Table XVIII.)

Normal cells, lymphocytes and peritoneal macrophages showed less sensitivity than tumor cells. No significant toxic effects were observed ( $p > 0.05$ ) along the full spectrum of used concentrations (Table XVIII.)

An evaluation of pulmonary metastasis incidence after 50 days showed that the administration of scorpion venom significantly reduced (0.8 mg/kg; 3.2 mg/kg) the onset of spontaneous lung metastases (Table XIX.)

Table XIX. Incidence of lung metastasis onset in Balb/c mice implanted with F311 murine mammary tumor. \*Statistically significant differences from control (p < 0.05.)

Group	Number of mice	Metastasis incidence	No. of metastasis nodules (range)
Control	6	4/6 66%	0-7
0,2 mg/kg	7	5/7 71%	0-7
0,8 mg/kg	5	2/5 42%	0-2*
3,2 mg/kg	5	2/5 42%	0-3*

5

#### Oral administration route

10 The effect of scorpion venom on an mammary adenocarcinoma model implanted in Balb c mice was evaluated. Four doses (6 mg/kg, 12.5 mg/kg, 25 mg/kg and 50 mg/kg) for the treatment groups were used. Controls were given a saline solution and all administrations were through oral route for 35 days. Tumor growth was monitored for 35 days.

15 The experimental groups administered with scorpion venom showed significant tumor growth inhibition (p < 0.05) compared to the control group (Figure 4.) The experimental groups showed a dose-response ratio during the 35 days of evaluation as to tumor progression retardation.

20 Table XX. Mean survival time of experimental groups implanted with 10<sup>6</sup> S-180 mice cells intraperitoneally and treated with *R. junceus* scorpion venom given orally.

Dose	Control	6 mg/kg	12,5 mg/kg	25 mg/kg	50 mg/kg
Survival time (days)	20	20,5	24	22,5	20

5 Table XXI. Survival time among experimental groups implanted with  $10^6$  S-180 mice cells intraperitoneally and treated with *R. juncus* scorpion venom given orally.

Dose	Control	6 mg/kg	12,5 mg/kg	25 mg/kg	50 mg/kg
Survival, %	0	26	37	22	0

10 The 12.5-mg/kg dose gave a longer mean survival time (24 days), followed by the 25-mg/kg dose (22.5 days) and the 6-mg/kg dose (20.5 days), while the mean survival time of controls was 20 days (Table XXI.) Similarly, the 12.5-mg/kg dose evidenced the highest survival percents by the time at which 100% of mice in the control group had died (Table XXI), while the 6-mg/kg and 25-mg/kg doses showed 26% and 22%, respectively. Notwithstanding these results, the longer survival time and the survival percents among the three experimental groups (6  
15 mg/kg, 12.5 mg/kg and 25 mg/kg) were not statistically significant. The 50-mg/kg dose showed similar values to those of controls in all cases.

#### Assay on the antiproliferative activity of fractions obtained from molecular exclusion chromatography

20

The effect of protein fractions on cell growth was determined in a similar way as that in Example 6. The study used 2 tumor cell lines: HeLa (human cervix carcinoma) and A549 (human lung carcinoma) and the normal MRC-5 cell line

(human lung fibroblasts.) Fractions were at a final 9 µg/mL-600 µg/mL concentration in wells.

The cytotoxicity evaluation of cell line fractions evidenced inhibited growth of tumor cells and little toxicity in normal cells for the LB-03 and LB-04 fractions. Table XXII shows the CC<sub>50</sub> for each of the purification fractions.

Table XXII. Relative molecular weights and mean cytotoxic concentration of fractions from molecular exclusion chromatography in tumor and normal cell lines.

10

<i>R. junceus</i> venoms fractions	Relative molecular weights*	Mean cytotoxic concentration (CC <sub>50</sub> ) (µg/mL)		
		Hela	A549	MRC-5
LB-01	30 kDa-72 kDa	835,3	420	245,1
LB-02	14 kDa- 30 kDa	208,7	250	276,9
LB-03	4 kDa - 8 kDa	140,1	116,6	439,2
LB-04	≤4 kDa	423,6	283	613,9

\*Relative molecular weights determined from the log PM vs V<sub>0</sub>V<sub>e</sub> calibration curve.

MW: Molecular weights of pattern proteins.

15 V<sub>0</sub>: Dead volume of column.

V<sub>e</sub>: Elution volume for each protein peak.

Fractions obtained from FPLC molecular exclusion chromatography were run in polyacrilamide gel electrophoresis with a 4-20% gradient to verify their protein composition, which appears in Fig. 7.

20

The LB-03 and LB-04 fractions have a low molecular weight protein composition and, additionally, they were the fractions which showed higher cytotoxicity on tumor cells (Hela and A549) and low toxicity on normal cells (MRC-5.)

These fractions were re-purified through high-resolution liquid chromatography using a C18 reverse-phase analytical curve. Two solutions were used as mobile phase: Solution A (0.12% trifluoroacetic acid (TFA) in water) and Solution B (0.10% TFA in acetonitrile.) Fraction component elution was done with gradual gradients from 0 to 70% of Solution B for 70 minutes and at a 0.5 ml/min flow and the fraction detection wavelength was 220 nm. The obtained pure peptides in tumor (Hela) and normal (CHO) cells were evaluated in a way similar to that described in Example 6 and their molecular weight and protein sequence were determined through mass spectrometry built in a high-resolution liquid chromatography device.

Eight peptides (RjLB-01, RjLB-03, RjLB-04, RjLB-05, RjLB-07, RjLB-08, RjLB-09 and RjLB-14) with high cytotoxic activity on tumor cells and low toxicity on normal cells were obtained. These results corroborate what was observed with whole venom and confirm the preferential toxicity of venom components on tumor cells.

Based on the purification of active components, their proportional presence in venom was determined (Table XXIII.)

Table XXIII. Proportion of active principles in venom composition and range of *in vitro* biological activity on tumor cells.

Active principle	Proportion of venom, %	<i>In vitro</i> biological activity range (%)
RjLB-01	1,5-20	0,945-1,89
RjLB-03	8-9	4,5-9
RjLB-04	0,5-1,0	0,445-0,89
RjLB-05	0,5-0,7	0,33-0,71
RjLB-07	0,5-0,8	0,5-1,0
RjLB-08	0,5-1,0	1,5-3,0

RjLB-09	0,3-0,6	3,65-4,1
RjLB-14	0,4-0,8	3,5-6,0

(pag. 24)

The molecular weights obtained for the RjLB-01, RjLB-03 and RjLB-04 peptides were 908 Da, 1964 Da and 4748,14 Da, respectively. The obtained sequences were compared to scorpion venom peptide data bases and no homology with previously described peptides was found, which is additional evidence of the novelty of results.

Another result from this invention is the formulation obtained as follows: Fifty to one hundred *Rhopalurus junceus* species scorpions were taken and their venom extracted by way of electric stimulation and diluted in 10-20mL distilled water. It was then clarified through 10 000 rpm centrifugation for 15 minutes to get rid of components such as mucus and cell debris. At the same time, their proteins were determined using the Lowry method and the result was a concentration of 5-15 mg/mL. Then the scorpion venom was diluted conveniently with distilled water as the only excipient to obtain a formulation whose concentration range was 0.05-0.1 mg/mL.

### **Brief description of figures**

20

Figure 1 shows the behavior of codeine (positive control), a central analgesic drug whose mean life fluctuates within 2-3 hours, which coincides with our results.

Figure 2 shows 1.5% agarose gel electrophoresis of DNA extracted from the A549 and Hela tumor cell lines. Venom was given at an end concentration of 0.5 mg/mL per well. DNA from each cell line was extracted after 24 and 48 hours.

25

Track M: Lambda DNA/Hind III molecular weight marker.

Track 1-3: A549 cell line; 1: DNA control without venom; 2: DNA extracted after 24 hours; 3: DNA extracted after 48 hours.

Track 4-6: Hela cell line; 4: DNA control without venom; 5: DNA extracted after 24  
5 hours; 6: DNA extracted after 48 hours.

Figure 3 shows the kinetics of tumor growth in the experimental groups. Tumor growth was monitored for 35 days. Tumor growth inhibition depended on the venom doses that were given. The statistical significance as per control was \*p < 10 0.05; \*\*p < 0.01, \*\*\*p < 0.001.

Figure 4 shows the kinetics of tumor growth in the experimental groups. Tumor growth was monitored for 35 days. Tumor growth inhibition depended on the venom doses that were given. The statistical significance as per control was \*p < 15 0.05; \*\*p < 0.01, \*\*\*p < 0.001.

Figure 5 shows the effect t of oral administration of scorpion venom on the incidence of experimental lung metastases. Statistically significant difference: \*\*p < 0.01, \*\*\*p < 0.001.

20

Figure 6 shows the *R. juncus* scorpion venom chromatographic profile in low-pressure liquid chromatography using a 12 HR10/30 Superose molecular exclusion column.

25 Figure 7 shows the polyacrylamide gel electrophoresis in reductive conditions. Fractions obtained from purification were applied using low-pressure liquid chromatography. Track 1: Molecular Weight Marker; Track 2: Whole Venom; Track 3: LB-01 Fraction; Track 4: LB-02 Fraction; Track 5: LB-03 Fraction; Track 6: LB-04 Fraction.

30

Figure 8 shows the concentration-response curve for pure peptides which were obtained from the re-purification of evaluated fractions. The evaluation was performed on Hela (human cervix carcinoma) tumor cells. The concentrations used were 6.25 µg/mL-400 µg/mL.

5

Figure 9 shows the concentration-response curve for pure peptides which were obtained from the re-purification of evaluated fractions. The evaluation was performed on CHO (Chinese Hamster Ovarium) non-tumor cells. The concentrations used were 6.25 µg/mL-800 µg/mL.

10

**Example 1 Acute inflammation model of croton oil-induced auricular edema in mice.**

OF-1 male mice weighing an average 18-22 g from the National Center for Laboratory Animal Production (CENPALAB) were used. The method described by CYTED (Ibero-American Programme for Science and Technology Development, Lima, November of 1996) was used. A 0.5%-acetone croton oil solution was used. Dexamethasone was dissolved in 0.5% CMC.

20 **Example 2 Cotton ball implantation model in rats**

Sprague-Dawley rats of 180g body weight from the National Center for Laboratory Animal Production (CENPALAB) were used.

25 The method for cotton ball implantation from CYTED (Ibero-American Programme for Science and Technology Development, Lima, November of 1996) was carried out.

Inflammation is the tissue response to damage. This includes enzyme involvement and activation, mediator release, fluid extravasation, cell migration and tissue rupture and repair (Vane, 1995.) It is well known that the anti-inflammatory effect 30 may result from a series of chemical agents and that there is a slight correlation between their pharmacological activity and chemical structure (Sertie, 1990.) This,

combined with the complexity of the inflammatory process, requires the use of various experimental models for carrying out a pharmacological assay. The cotton pellet granulose model in rats is a frequently used assay to study the effect on chronic inflammation conditions (Elieter, 1999.) Three inflammation phases after pellet implantation have been demonstrated. The last phase is that of cell proliferation occurring between the third and sixth days. This phase may be inhibited by anti-inflammatory steroids such as dexamethasone and by non-steroidal anti-inflammatory drugs (Sw, 1972.)

10 The animals were sacrificed 7 days after the implantation of cotton plugs through the established euthanasia method and the pellets were extracted and studied. The pellet's end- and initial-weight difference was considered to be the granulomatose tissue produced.

### 15 **Example 3 Inflammatory angiogenesis model**

Sprague-Dawley male rats from CENPALAB with 180-240 g body weight were used.

Inflammatory angiogenesis is a complex process involving a series of different but basically similar molecular mechanisms which develop in an angiogenic cascade.

20 Six days after granuloma formation was induced, the granuloma was well defined and palpable in the control group, which coincides with the results reported by Primelles in 2001. In the case of animals given venom doses, the granulomas were smaller at touch and a macroscopic observation of them showed less-defined ends and they were not so attached to the epidermis.

25

### **Example 4. Analgesic activity**

- Model of acetic acid-induced contorsions in mice

The method described in CYTED was followed.

30 OF1 male mice weighing an average 20-25g from the National Center for Laboratory Animal Production (CENPALAB) were used.

### **Intraperitoneal route administration**

Doses of 1-, 2.5- and 7.5-mg/kg *R. junceus* venom were inoculated intraperitoneally. Thirty minutes later, the experimental animals were administered 0.1 mL of a 3-percent acetic acid solution intraperitoneally and the number of contorsions/animal was recorded for 10 minutes beginning with the first contorsion observed.

#### **Oral route administration**

Doses of 1-, 5-, 10-, 15-, 20- and 50-mg/kg *R. junceus* venom were administered orally. One hour later, the experimental animals were administered 0.1 mL of a 3-percent acetic acid solution intraperitoneally and the number of contorsions/animal was recorded for 10 minutes beginning with the first contorsion observed.

#### **Example 5 Evaluation of antioxidative activity.**

The *in vitro* anti-oxidative activity by *Rhopalurus junceus* venom was evaluated through the DNA protective effect in Copper-Phenanthroline and Bleomycin-Iron systems oxidative processes. The venom showed anti-oxidative activity as it protected DNA from peroxidation processes.

The Copper-Phenanthroline and Biomycin-Iron systems showed that the *Rhopalurus junceus* derivative in the above-described formulations has no pro-oxidative effect on DNA. The absorbance values obtained with various *Rhopalurus junceus* derivative concentrations are lower than those obtained with the positive control. Tables XVI and XVII show the results from such evaluation.

#### **Example 6. In vitro cytotoxicity in a panel of tumor and normal cells**

The effect of venom on cell growth was seen in the MTT assay, which measures cell proliferation resulting from the metabolic reduction of this (yellow) tetrazolium salt by mitochondrial dehydrogenated enzymes. The resulting compound (blue formazan) can be made soluble and quantified spectrophotometrically

Nine tumor cell lines were used in the study: HeLa (human cervix carcinoma), HEp-2 (human laryngeal epidermoid carcinoma), NCI-H292 (human lung mucoepidermoid carcinoma), A549 (human lung carcinoma), U937 (human histiocytic lymphoma), L929 (murine fibrosarcoma), S-180 (murine sarcoma), and F311 (murine breast sarcoma.) Equally, 3 normal cell lines were used: MRC-5 (human lung fibroblasts), Vero (African green monkey normal kidney cells), and

MDCK (normal dog kidney cells.) Peritoneal macrophages (extracted from Balb/c mice peritonea) and lymphocytes (extracted from Balb/c mice spleens) were also evaluated. Cells were grown within culture flasks in a minimal essential medium (MEM) or in a RPMI-1640 medium, depending on cell culture characteristics, and added 2 mM glutamine, non-essential amino acids, 10% bovine fetal serum (BFS), and 100 IU-100 µg/mL penicillin-streptomycin. Each one was incubated in a humid atmosphere at 37°C and 5-percent CO<sub>2</sub> till a single-layer was formed. Each cell line was separated by way of a 0.25% trypsin-EDTA solution and prepared at a 2 x 10<sup>5</sup> cell/mL concentration after being counted in a Neubauer chamber.

10 The assay was done in 96-well, flat-bottom cell culture polystyrene dishes (*Coming Inc. costar<sup>R</sup>.*) 50 µL of each cell line was poured into each well and incubated at a 5-percent CO<sub>2</sub> and 37°C atmosphere for 24 hours. After such time, 50 µL medium containing previously dissolved venom was added. Final venom concentrations were 0.1 mg/mL, 0.25 Mg/mL, 0.5 mg/mL, 0.75 mg/mL and 1 mg/mL in wells. All final cell line concentrations were 10<sup>4</sup> cells/well. The bovine fetal serum (BFS) was used in the medium at 10%.

Dishes were incubated again at a 5-percent CO<sub>2</sub> and 37°C atmosphere for three days. After such time, a 10 µL MTT sterile solution (5 mg/mL tetrazolium salts in sterile PBS) was added to each well and incubated under the same conditions for 4 hours. Finally, the medium was poured off and a 200 µL/well dimethyl sulfoxide (DMSO) solution was added and incubated at 37°C for 30 minutes in a humid atmosphere. The optical density (OD) was read on a Revelation Dynex Technologies ELISA MRX microdish reader at 560 nm with 630 nm as reference. Each fractional concentration was done three times and the assay was performed four times.

For the concentration-response curves analysis, the cell proliferation percent was graphically obtained from the formula  $(1-OD \text{ (sample)}/OD \text{ (control)}) \times 100$  against the different venom concentrations. Mean cytotoxic concentration was expressed as CC<sub>50</sub>, which is the venom concentration that provokes a 50-percent decrease in the number of viable cells (MTT absorbance) compared to untreated controls and appears in Table XV for each of the evaluated cells.

**Example 7. Apoptosis study**

The study for determining apoptosis was done through DNA fragmentation. The HeLa and A549 cell lines were used. Results are shown in Figure 2. The characteristic DNA fragmentation of apoptosis was observed in the corresponding tracks of HeLa cells treated with venom, while a single intact chromosomal DNA band in control wells and in the A549 cell line was observed. These results show that scorpion venom may induce cell death through both mechanisms –apoptosis and necrosis.

**Example 8. Antitumor activity in solid tumors F311breast adenocarcinoma experimental model . Intraperitoneal administration route**

The effect of scorpion venom on a mammary adenocarcinoma model implanted in Balb c. mice was evaluated. Three doses (0.2 mg/kg, 0.8 mg/kg and 3.2 mg/kg) were used for the treatment groups. Controls were administered a saline solution intraperitoneally. Tumor growth was monitored for 35 days. Fifty days after the implantation of the tumor the animals were sacrificed, their lungs were extracted and pulmonary metastasis was searched for.

The experimental groups treated with scorpion venom showed significant tumor growth inhibition ( $p < 0.05$ ) compared to the control group (Figure 3.) The experimental groups showed a dose-response ratio during the 35 days of evaluation as to tumor progression retardation. The significant reduction of tumor growth in the treated groups indicates that *R. junceus* scorpion venom has an antitumor effect as it influences tumor growth, at least during the evaluation period.

**Example 9 F311 breast adenocarcinoma. Experimental model. Oral administration route**

The effect of scorpion venom in a breast adenocarcinoma model that was injected in Balb c mice was evaluated. Four doses (6mg/kg, 12,5 mg/kg, 25 mg/kg and 50 mg/kg) were used for the treatment groups, the control group was administered a saline solution orally. Tumor growth was monitored for 35 days.

The experimental groups treated with scorpion venom (12, 5 mg/kg, 25 mg/kg and 50 mg/kg) showed significant tumor growth inhibition ( $p < 0.05$ ) when compared to the control group (Figure 4.) The significant decrease in tumor

progression that was found in the treated groups demonstrates the antitumor effect of the *R. junceus* scorpion venom, as it affected tumor growth at least during the evaluation period.

5 **Example 10.** Antitumor activity in ascitic tumors. Experimental sarcoma model (S-180)

The effect of scorpion venom in a murine sarcoma model implanted in the peritoneum of NMRI mice was evaluated. Four doses (6 mg/kg, 12.5 mg/kg, 25 mg/kg and 50 mg/kg) for treatment groups were used. The control group was  
10 given a saline solution. The venom was administered daily 24 hours after the implantation of the tumor until all experimental groups died. Table XX shows the survival time results with the treated animals and controls. Table XXI shows the survival percents among experimental groups.

15 **Example 11.** Purification and identification of venom proteins as active principles.

In order to separate whole protein content, the whole venom was dissolved in 0,1 M ammonium acetate (NH<sub>4</sub>Ac) and centrifuged at 10 000 rpm for 15 minutes. The supernatant was put in an AKTA FPLC (Amersham Pharmacia Biotech) low-pressure liquid chromatography equipment with a 12 HR 10/30 Superose filtration  
20 gel column measuring 10 x 300 mm. The column was balanced with 0.1M NH<sub>4</sub>Ac and the material mixed with same solvent at a flow rate of 0.5 mL/min. Absorbance was monitored at an optical density (OD) of 280 nm for 72 minutes. The 75 HR 10/20 Superose molecular exclusion column was calibrated with a pattern protein kit including ribonuclease A (13.7 Kda), chemotripsinogen (25 Kda), ovoalbumin  
25 (43 Kda), albumin (67 Kda) and blue dextrane 2000. A pattern curve was drawn to determine the relative molecular weights of the various protein fractions obtained during chromatography. The results from chromatographic runs appear in Figure 6.

**Example 12** Clinical studies about the formulation given to human cancer patients

30 The purpose of the study was to assess life quality in cancer patients. The subjects included in the study were patients of both sexes with histologically

confirmed cancer at any stage. A document was written which stated the informed consent of patients and a summary of the clinical record issued by the treating oncologist. The document included an evaluation of the clinical condition of patients as followed by their physicians in the hospital during their clinical evolution. Follow-up periodicity was no less than two months. Follow-up took place for a year. The formulation was prepared in 40-mL flasks with 0.05-0.1 mg/mL concentrations. Flask content was diluted in distilled water used as excipient to complete 1 liter. The product was administered daily by oral route and the recommended doses depended on patient condition and histological diagnosis.

A total of 100 patients were included in the study and the main evaluated cancer locations were breast, prostate, colon, lung, brain and pancreas. The administration of the product did not cause any adverse reaction at any moment during treatment, which coincided with observations during pre-clinical studies. All cases improved their quality of life as evidenced by an improvement in their main clinical variables such as less or no dysnea and coughing in all lung cancer patients. Many patients showed better radiological test results in the form of lesion stabilization in some cases and disappearance in others. Additionally, hematological variables were stabilized and pain and swelling reduced. Over 50% of the patients treated with the invented formulation for a year had a longer survival time than the one estimated for some of the studied conditions.

### **Example 13.**

#### Clinical studies of the formulation in human cancer patients..

The objective of the study was the evaluation of life quality in cancer patients. Patients of both sexes with histological confirmation of cancer in any stage were used to be included as study individuals. A document was prepared which contained the patient's consent act and the summary of the clinical record issued by the primary health care oncologist.

The evaluation of the clinical behavior of patients was included in the document and the evaluation was followed up through the clinical progress and conducted by the specialists from the patients' origin hospitals. The periodicity of the follow-up

was of at least two months. The follow-up was carried out during 1 year. The formulation was prepared in bottles with a volume of 40 mL with concentrations between 0.05-0.1 mg/mL. The flask was diluted in distilled water used as excipient until completing 1 liter. The product was administered on a daily basis through the oral route and the recommended dose depended on the patient's stage and histological diagnosis.

A total of 100 patients were included in the study and the main locations for cancer were, breast, prostate, colon, lung, brain and pancreas. In no case the administration of the product caused adverse reactions during the treatment which coincided with what was observed in the preclinical studies. In all cases it was observed an increase in life quality including an improvement of the main clinical variables such as decrease or disappearance of dyspnea and coughing in all cases of lung cancer patients. In many patients it was verified an improvement in the x-ray tests results as their lesions became stable in some case and in others lesions disappeared. In addition to this, the stabilization of the hematological variables was achieved and there was a reduction of pain and inflammation. In over 50 % of the patients treated for 1 year with the formulation object of the invention, the survival period estimated for some of the pathologies studied was exceeded.

#### **Example 14. Vidatox ® 30 CH clinical studies**

**VIDATOX ® 30 CH** is a homeopathic biotherapeutical drug developed at the Homeopathy Laboratory of LABIOFAM. Its active ingredient is *Rhopalurus junceus* scorpion venom in a 30 centesimal dilution. It comes in the form of drops in a 33% alcohol vehicle.

The studies carried out in 174 patients, of both sexes, having specific cancer treatments demonstrated the adjuvanting effect of **VIDATOX ® 30 CH** for treating cancer in different body location, (lung, prostate, breast, colon, pancreas, t. lymphoid, brain, rectum etc.) Its results show that 96 % of patients administered with the product had a survival of over 12 months, that 90% of the patients reported improvement in their clinical symptoms seen by physicians and that

among these 63 patients, pain (as the predominant symptom) for 62 % of them evolved to a moderate form, which did not require relief treatment, that the 27 % of them reported no pain and none of them reported adverse reactions to the treatment.

5

**CLAIMS**

- 5 1) Peptide called RjLB-01, obtained from scorpion venom and characterized by having 544.42 Da molecular weight and SEQ. DI No. 1 amino acid sequence.
- 2) Peptide called RjLB-03, obtained from scorpion venom and characterized by having 1964.0 Da molecular weight and SEQ. DI No. 2 amino acid sequence.
- 10 3) Peptide called RjLB-04, obtained from scorpion venom and characterized by having 4748.14 Da molecular weight SEQ. DI No. 3 amino acid sequence.
- 4) Peptide called RjLB-05, obtained from scorpion venom and characterized having 908.0 molecular weight of Da and SEQ. DI No. 4 amino acid sequence.
- 15 5) Peptide called RjLB-07, obtained from scorpion venom and characterized by having 707.03 Da molecular weight and SEQ. DI No. 5 amino acid sequence.
- 6) Peptide called RjLB-08, obtained from scorpion venom and characterized by having 712.42 Da molecular weight and SEQ. DI No. 6 amino acid sequence.
- 20 7) Peptide named RjLB-09, obtained from scorpion venom and characterized by having 1203.44 Da molecular weight and SEQ. ID No. 7 amino acid sequence.
- 8) Peptide called RjLB-014, obtained from scorpion venom and characterized by having 5930. 45 Da molecular weight and SEQ. DI No. 8 amino acid sequence.
- 25 9) Pharmaceutical compositions that are obtained from *Rhopalurus junceus scorpion venom*, characterized by having peptides as active principles with high cytotoxic activity on tumor cells, mixed with distilled water as excipient
- 30 10) Pharmaceutical compositions as per claim 9 which are processed-homeopathically.

- 11) Pharmaceutical compositions as per claim 9, containing at least one peptide according to claims 1-8, which has antitumor activity, and such selected peptide having any of the described amino acid sequence.
- 5 12) Pharmaceutical compositions as per claim 11 characterized by having a mix of peptides contained in *Rhopalurus junceus* scorpion venom with the following concentrations: RJL-01, at a 1,5-2,0% range; RJLB-03, at a 8-9% range; RJLB-07, in a 0,5-0,8% range; RJLB-08 at a 0,5-1,0% range; RJLB-09, at a 0,3-0,60% range; RJLB-14, at a 0, 4-0-8% range, diluted in 10-20 mL distilled water.
- 10 13) Pharmaceutical compositions, as per claim 12, processed homeopathically.
- 14) Pharmaceutical compositions, as per claims 9, 10,11, 12 and 13, used in formulations to be administered by oral, topical, parenteral, rectal, vaginal and aerosol routes.




Figure 1




Figure 2

Figure 3





Figure 4






Figure 5




Figure 6




Figure.7

Figure 8













Figure 9


Determination of cell proliferation




Determination of cell proliferation




Determination of cell proliferation



Determination of cell proliferation



Determination of cell proliferation



Determination of cell proliferation




Figure 9

4246891\_1  
LISTA DE SECUENCIAS

<110> Grupo Empresarial LABIOFAM

<120> Péptidos del veneno de escorpión *Rhopalurus junceus* y composición farmacéutica.

<130> 01-00001

<140> PCT/CU2011/000006

<141> 2011-09-27

<150> CU2010-0186

<151> 2010-09-27

<160> 8

<170> PatentIn Ver. 2.1

<210> 1

<211> 10

<212> PRT

<213> *Rhopalurus junceus*

<400> 1

Arg Thr Gly Ser Leu Leu Thr Leu Ala Arg  
1 5 10

<210> 2

<211> 17

<212> PRT

<213> *Rhopalurus junceus*

<400> 2

Asp Leu Phe Asp Glu Leu Asp Pro Gln Lys Asp Glu Leu Asp Gln Gly  
1 5 10 15

Ser

<210> 3

<211> 43

<212> PRT

<213> *Rhopalurus junceus*

<400> 3

Phe Glu Leu Lys Asp Leu Glu Gly Gln Thr Leu Tyr Leu Lys Asp Leu  
1 5 10 15

Glu Gly Lys Thr Cys Ser Gly Gly Glu Leu Asp Lys Glu Glu His Cys  
20 25 30

Gly Gly Asn Glu Leu Asp Ser Gln Gly Phe Asn  
35 40

<210> 4

<211> 8

<212> PRT

<213> *Rhopalurus junceus*

<400> 4

Met Leu Leu Asp Asn Val Gly Phe  
1 5

<210> 5  
 <211> 7  
 <212> PRT  
 <213> Rhopalurus junceus

<400> 5  
 Asp Met Gly Ala Leu Leu Ser  
 1 5

<210> 6  
 <211> 17  
 <212> PRT  
 <213> Rhopalurus junceus

<400> 6  
 Phe Asp Glu Thr Ala Lys Asp Glu Leu Leu Gly Phe Leu Gly Leu Phe  
 1 5 10 15

Asn

<210> 7  
 <211> 12  
 <212> PRT  
 <213> Rhopalurus junceus

<400> 7  
 Leu Pro Cys Ala Leu Asn Asp Gly Gly Leu Cys Lys  
 1 5 10

<210> 8  
 <211> 50  
 <212> PRT  
 <213> Rhopalurus junceus

<400> 8  
 Val Met Gln Asp Gln Tyr Leu Ile Ile Asn Gly Val Trp Ser Ile Val  
 1 5 10 15

Phe Phe Leu Glu Val Ser Ile Leu Val Ile His Ile Phe Leu Leu Arg  
 20 25 30

Glu His Glu Val Phe Val Val Arg Arg Gly Asp Glu Thr Ala Lys Asp  
 35 40 45

Glu Leu  
 50